Poland· PL-100476689
Beyfortus
A nirsevimab product containing nirsevimabum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nirsevimab is registered in 14 of 19 countries.
Countries holding a registration under ATC J06BD08 (nirsevimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Nirsevimab · ATC J06BD08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Nirsevimabum
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- J06BD08
- ATC class
- Nirsevimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991537814
- gtin05909991537807
- gtin05909991537821
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nirsevimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBEYFORTUSSanofi Winthrop Industrie, Gentilly
- United KingdomBeyfortus 100mg/1ml solution for injection pre-filled syringesSanofi
- SpainBEYFORTUS 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADASanofi Winthrop Industrie
- SwitzerlandBeyfortus
- IcelandBeyfortusSanofi Winthrop Industrie
- NorwayBeyfortusSanofi Winthrop Industrie
- SwedenBeyfortus 100 mg Injektionsvätska, lösning i förfylld sprutaSanofi Winthrop Industrie
- United StatesBEYFORTUSSanofi Vaccines US Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beyfortus
- Liechtenstein · Beyfortus
- Norway · Beyfortus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/16f6c1e1-e453-4a90-96a5-366317f467f1 GET /v1/drugs/16f6c1e1-e453-4a90-96a5-366317f467f1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "100 mg",
"packaging": "05909991537814 ¦ Rp ¦ EU/1/22/1689/005 ¦ 147892\n1 amp.-strzyk. 1 ml ¦ 2 igły \n05909991537807 ¦ Rp ¦ EU/1/22/1689/004 ¦ 147893\n1 amp.-strzyk. 1 ml\n05909991537821 ¦ Rp ¦ EU/1/22/1689/006 ¦ 147894\n5 amp.-strzyk. 1 ml",
"substance": "Nirsevimabum 100 mg",
"common_name": "Nirsevimabum",
"pl_product_id": "100476689",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nirsevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.